Vivos to Partner with SOD Sciences in Chronic Disease Testing

VERO BEACH, Fla., October 20, 2026 /CourierPR/ -- SOD Sciences, a precision-health company, today announced a strategic partnership with Vivos Therapeutics, Inc., a Nasdaq-listed leader in the treatment of obstructive sleep apnea. The collaboration unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic-disease patients.

Vivos has acquired an 11% equity interest in SOD Sciences, a 50% ownership interest in SOD's pseudohypoxia patent, and a 50% ownership interest in SOD's pseudohypoxia early-warning test, the ReBalU Primed Cell Test, in exchange for $12,000,000 of Vivos Series D Convertible Preferred Stock, convertible at $0.15 per share into 80,000,000 shares of Vivos common stock and subject to a 4.99% beneficial ownership blocker. SOD retains ownership of its other patents and its ReBalU Protocol.

The partnership at a glance includes Vivos, a Nasdaq-listed leader in the treatment of obstructive sleep apnea, becoming an 11% shareholder in SOD Sciences, and SOD becoming a holder of Vivos convertible preferred stock. SOD and Vivos each own 50% of SOD's pseudohypoxia patent. SOD and Vivos share 50/50 in the contribution margin on every ReBalU Primed Cell Test sold, through every channel, by either company. SOD and Vivos market the ReBalU Protocol to Vivos's customers on a 50/50 basis. The ReBalU Primed Cell Test is marketed nationwide, to the more than 2,600 sleep centers in the United States and to chronic-disease practices. Nearly 500,000 patients are targeted by SOD's channels with Cleveland Clinic Weston, American Health Associates (AHA), and Vivos.

The ReBalU Protocol, SOD's lead product family, is built on SOD's founding principle: almost all chronic diseases stem from an imbalance in the body's antioxidant system. That imbalance begins with genetic insufficiencies in key antioxidant alleles. Life insults then drive key biomarkers in the wrong direction until the reduced glutathione reserve falls below the individual's critical point, and chronic disease follows. Chronic disease accounts for 90% of the nation's $5.3 trillion in annual health care spending.

The ReBalU Protocol works in three steps: a CLIA laboratory test measures the individual's antioxidant genotype and reduced glutathione reserve. A patent-pending, GRAS-based combination of the ReBalU gummie and a swallowable mouthwash raises the body's own endogenous butyrate and DHA to rebuild the reserve. The individual is tested again to confirm that the reserve has improved.

The ReBalU Protocol is a medical food. SOD is about to begin an Institutional Review Board study of the ReBalU Test/Treat/Retest Protocol at Cleveland Clinic Weston, which SOD believes will demonstrate the protocol's ability to improve the reduced glutathione reserve through increased endogenous butyrate together with DHA.

Pseudohypoxia is a state in which a cell behaves as if it is starved of oxygen even when oxygen is present. The cell switches on its hypoxia survival program, led by the protein HIF-1α, and shifts its metabolism away from mitochondrial respiration toward glycolysis, the same shift seen in chronic disease and cancer. In obstructive sleep apnea, the driver is the repeated cycle of oxygen desaturation and reoxygenation that occurs every night. Intermittent hypoxia raises HIF-1α and switches on its target genes, including those for glycolysis, and each reoxygenation sends a burst of oxidative and nitrosative stress through the cell that drains its glutathione reserve.

The most valuable patients in the U.S. medical system are the ones already diagnosed, already in a clinician's care, and already carrying the chronic conditions that drive cost. Through American Health Associates, the Sleep Center of Nevada, Cleveland Clinic Weston, and more than 2,600 sleep centers, Vivos and SOD now reach 500,000 identified patients who need exactly what we sell. Vivos treats the airway, ReBalU restores the cell's antioxidant reserve, and the pseudohypoxia test shows whether it is working and brings the patient back every ninety days. No other company owns all three, and every new clinic we add increases the value of the whole.

Vivos's FDA-cleared oral appliances stop the desaturation cycles at their source. The ReBalU Protocol rebuilds the reduced glutathione reserve. The quarterly retest shows the change.

SOD Sciences, Inc. is a precision-health company and the developer of the ReBalU Protocol, a genetics- and biomarker-guided test/treat/retest medical food that measures and rebuilds the body's antioxidant reserve, and of the ReBalU Primed Cell Test, a pseudohypoxia early-warning test performed by American Health Associates as its CLIA laboratory. Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for patients with sleep-disordered breathing, including obstructive sleep apnea. Its FDA-cleared oral appliances offer a non-surgical, non-invasive alternative to CPAP.